Related Experiment Videos
Prognostic indicators in early breast cancer
J A Figueroa1, D Yee, W L McGuire
1Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7884.
The American Journal of the Medical Sciences
|March 1, 1993
Summary
Adjuvant systemic therapy for early breast cancer shows modest relapse reduction but not improved survival. Identifying high-risk patients using prognostic factors like tumor size is crucial for targeted treatment.
Area of Science:
- Oncology
- Breast Cancer Research
- Clinical Trials
Background:
- Axillary node-negative breast cancer affects ~115,000 patients annually.
- 20-30% of these patients face disease relapse and mortality.
- Current adjuvant systemic therapy offers modest recurrence reduction but lacks consistent survival benefits.
Purpose of the Study:
- To evaluate the efficacy of adjuvant systemic therapy in axillary node-negative breast cancer.
- To identify reliable prognostic factors for risk stratification.
- To guide therapeutic decisions for improved patient outcomes.
Main Methods:
- Review of clinical trial data on adjuvant systemic therapy.
- Analysis of prognostic factors including tumor size, nuclear grade, and proliferative indexes.
- Investigation of biological markers such as hormone receptors and gene expression.
Main Results:
- Clinical trials show a modest impact on disease recurrence but not consistent improvements in overall survival.
- Tumor size, nuclear grade, and proliferative indexes correlate with recurrence risk.
- Hormone receptors, proto-oncogenes, and tumor suppressor genes show potential as prognostic indicators.
Conclusions:
- Generalized use of systemic therapy in this subgroup is not yet justified.
- Prognostic factors are essential for identifying high-risk patients.
- Larger clinical trials are needed to validate these parameters for routine clinical use.